which may be linked to the conjugation technology used in the drug and features as a black box warning on the product's label. The risk is said to be behind the somewhat slow take-up of Enhertu ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

US sales alone increased 35% year-on-year to ¥219.7 billion. The global product sales forecast for ENHERTU in FY2024 was revised upward to ¥539.9 billion, reflecting strong performance in HER2 ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

Enhertu is fast becoming a major growth product for Daiichi Sankyo and AZ, with sales across the two companies reaching $1.77 billion in the first six months of the year, up from $1.16 billion in ...

Daiichi Sankyo and AstraZeneca’s (AZN) Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...